Alaunos Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $<0.1 | $<0.1 | $<0.1 | $2.9 | $0.4 |
| Operating income | -$4.2 | -$4.8 | -$34.3 | -$35.1 | -$77.5 |
| Net income | -$4.2 | -$4.7 | -$4.7 | -$37.7 | -$78.8 |
| Balance Sheet | |||||
| Total debt | — | — | — | $16.8 | $24.1 |
| Cash Flow Statement | |||||
| Free cash flow | -$3.0 | -$5.0 | -$30.3 | -$29.4 | -$64.8 |
| Share repurchases | — | — | $0.0 | $<0.1 | $0.0 |
Shares outstanding 2.5M · Free float 62.0%
Annual filing data through FY ended December 31, 2025; float as of September 25, 2026.